George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
You can guarantee the word ‘significant’ will not be used when the results of the Brazil trial are published. Numbers are just way too small to comment on whether it has been effective or not. Really they’re too small to ensure it’s safety profile is acceptable. Much bigger trial required IMO
I think they/it will say ‘you can’t make any judgement on clinical efficacy from a paltry 39 patients’
And they would be right
Just been vaccinated. So far I haven’t noticed any fish. Cabbage, nine desk worm news pjs.
Sexy monkeys!
If so then the term ‘school boy error’ doesn’t even come close.
That’s the difficult isn’t it. He’s either a) as dumb as a stick or b) making stuff up to appease share holders. Neither of which are great. And before anyone says blah look at his publications I know loads of eminent clinicians who are as daft as a brush
Think they’ve signed off for Christmas. News maybe in January when we’re 50p. What a load of crap
And the record for the fastest broken promise to shareholders goes to....
70p here we come
Agreed. More ‘jam tomorrow ‘ stuff, which we’ve come to expect when there’s no actual news to report. Lame
Davey is bang on. All I’m saying
One hopes. Otherwise cue more vague promises and optimism
Everyone see this?
https://www.nejm.org/doi/full/10.1056/NEJMoa2031304
Oh yeah Thanksgiving.
Less Yanky spanky for us then
Holy cream on a cracker! 79% reduction in developing severe COVID, no systemic side effects (unlike IV prep where they’re significant)
Very good news as I felt one of the major risks was that inhalational delivery would be inferior given the fact that the inflammatory response is systemic, with lots of vascular involvement (clotting etc.)
Depends on your perspective. Inhalational delivery is actually a pain in the bum for me (critically ill patients, very breathless either on tight fitting CPAP mask or mechanically ventilated). IV is piece of cake.
Why I’m excited about this stuff is it’s bringing this technology to a whole new group of patients. I’ve never given a mab to anyone in my 15 years clinical practice, and it’s like someone has opened a box of additional therapies I can consider for all those patients who previously would just get a whacking dose of steroids. Alongside the obvious candidates of vasculitidies and autoimmune disorders, there’s post cardiac arrest patients (https://www.medscape.com/viewarticle/941530) and the acute transplant rejections that end up on ICU.
Now they’re reaching a far wider audience and clinicians are gaining better understanding of how and when to administer, we are going to see an exponential rise in their use.
Another paper showing IL6 inhibition potentially reducing in hospital mortality for Covid 19. Signal looks strongly positive but degree of certainty fairly low due to low numbers. Interesting because they combined trials with both Toc and sarilumab, making it look like a more generic effect. I.e. inhibition of IL6 by any means will hopefully result in benefit
https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa717/5995842
Ha! Nope, just raised there. I actually work in the North West.
https://www.health-ni.gov.uk/sites/default/files/publications/health/tocilizumab-position-statement-251120.pdf
Also had a separate comms from the DoH to ICUs wanting time start using it straight away outside of a clinical trial setting:
Product Details
Tocilizumab (RoActemra®) is supplied to the UK by Roche Chugai. It is a humanised monoclonal antibody against the interleukin-6 (IL-6) receptor
Arrangements are being made with Roche to secure sufficient supply to the UK to meet potential COVID-19 treatment requirements, alongside existing (licenced) clinical indications. The additional supply will be managed by providing an indicative maximum order ‘cap’ by hospital / trust (based on modelled intensive care activity), for those organisations who have formally confirmed they wish to participate. Retrospective reimbursement of medicines costs will continue to be managed as usual through the excluded drugs funding route in England. Further advice will follow for Northern Ireland, Scotland and Wales.
Maintain access to intravenous tocilizumab for existing (non COVID-19) indications including rheumatoid arthritis (where appropriate), paediatric indications and treatment of cytokine storm (CRS) following CAR-T therapy. With the exception of CRS, patients can alternatively be switched to the subcutaneous formulation of tocilizumab. To assess suitability for available subcutaneous formulations for rheumatoid arthritis (RA) and paediatric arthritis patients, please consult the relevant Summary of Product Characteristics
Provide regular updates on the stock position to trust / hospital and regional procurement pharmacy lead / chief pharmacists.
Thanks for those SK
‘Tiziana thinks the drug—NI-1201—can best rival products by binding to both membrane-bound and soluble IL-6R. Roche’s rheumatoid arthritis drug Actemra only binds to membrane-bound IL-6R.’
I wonder what Actemra’s current market value is??
Ongoing. Interesting stuff
Looks like benefit is in addition to the benefit from Dex, which is good. They’ve only stopped the control arm so they’re still recruiting to the other arms, which means full analysis of results will be three weeks from now. Roughly
Are you simples or something Examiner? The drug that they predicted back in August may be effective against Covid is imminently about to be revealed as the worlds best treatment for the disease. Do you think that’s not relevant for someone looking to invest, given it’s an established part of their pipeline and they’re well placed to commence the worlds first trial of it via an inhaled route for Covid patients?
RNS Number : 8920W
Tiziana Life Sciences PLC
24 August 2020
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for Covid-19 and other pulmonary diseases
New York/London, 24 August, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the United States Patent and Trademark Office ("USPTO") has granted a patent for methods and use of fully human monoclonal antibody (mAb; TZLS-501) that recognizes both IL-6 receptor (IL-6R) and IL-6 receptor complex with IL-6 (IL-6R/IL-6) for prophylactic and therapeutic intervention for human diseases. The Company initially entered into a world-wide exclusive license from Novimmune, SA., a Swiss Biotechnology company in 2017. The license is currently maintained with Bristol Myers Squibb. The patent (No. 10,759,862) will be published by the USPTO on September 1, 2020. The grant of this additional patent on TZLS-501 is of particular significance for the potential treatment of COVID-19 and other pulmonary diseases such as acute respiratory distress syndrome (ARDS).
The major distinguishing feature of TZLS-501 is that it acts via a dual mechanism by not only inhibiting IL-6R signaling but also depleting circulating levels of IL-6. This distinctive feature of TZLS-501, a fully human anti-IL-6R mAb, makes it potentially suitable for treatment of COVID-19 and ARDS. For example, COVID-19 patients often develop an uncontrolled immune response ("cytokine storm") resulting in severe damage to the lung tissue which could lead to respiratory failure. Many studies have also indicated excessive levels of IL-6 in the lungs and in the blood of these patients, and it is believed that the cytokine storm in lungs is primarily due to excessive levels of IL-6. Hence, direct inhalation delivery of TZLS-501 to the lungs using a hand-held nebulizer has the potential to deplete circulating levels of IL-6 and inhibit IL-6R signaling thus providing immediate relief to COVID-19 patients.
"The granting of this patent along with our previously filed patent application on inhalation delivery of anti-IL-6 mAbs strengthens our intellectual property for the treatment of lung diseases. We are expediting the clinical development of TZLS-501, GMP manufacturing, simultaneously developing inhalation delivery directly to the lungs using a nebulizer and conducting the inhalation safety toxicology studies in Cynomolgus monkeys. Completion of these studies will enable us to file an IND and initiate a clinical trial in COVID-19 patients by Q1 2021.